LEADER 01218nam1 2200421 450 001 990000867540203316 005 20100107171643.0 035 $a0086754 035 $aUSA010086754 035 $a(ALEPH)000086754USA01 035 $a0086754 100 $a20020111d--------km-y0itay0103----ba 101 $aita 102 $aIT 105 $a||||||||001yy 200 1 $a<> stato per Romagnosi$fLuca Mannori 210 $aMilano$cGiuffré 215 $av$d23 cm 410 $12001 606 0 $aRomagnosi, Gian Domenico 606 0 $aDiritto pubblico$xTeorie$zSec. 19. 676 $a342.00924 700 1$aMANNORI,$bLuca$0141818 801 0$aIT$bsalbc$gISBD 912 $a990000867540203316 951 $aXXX.A. Coll. 92/ 12 (COLL. ATK)$bEC$cXXX.A. Coll. 92/ 12 (COLL. ATK) 951 $aCOLL XXIX$b1805 DIRCE 959 $aBK 969 $aGIU 969 $aDIRCE 979 $aPATTY$b90$c20020111$lUSA01$h1141 979 $c20020403$lUSA01$h1731 979 $aPATRY$b90$c20040406$lUSA01$h1700 979 $aDIRCE$b90$c20081030$lUSA01$h1048 979 $aDIRCE$b90$c20081030$lUSA01$h1048 979 $aRSIAV3$b90$c20100107$lUSA01$h1716 996 $aStato per Romagnosi$9648619 997 $aUNISA LEADER 02172oam 2200325z- 450 001 9910555194803321 005 20210108010103.0 010 $a1-119-07030-9 010 $a1-119-07029-5 010 $a1-119-07015-5 035 $a(CKB)4330000000008301 035 $a(MiAaPQ)EBC5452560 035 $a(EXLCZ)994330000000008301 100 $a20180812cuuuuuuuu -u- - 101 0 $aeng 200 00$aOligonucleotide-based drugs and therapeutics $epreclinical and clinical considerations for development /$fedited by Nicolay Ferrari, Rosanne Seguin 210 $cJohn Wiley & Sons, Inc 311 $a1-118-53733-5 327 $aMechanisms of oligonucleotide actions -- The medicinal chemistry of antisense oligonucleotides -- Cellular pharmacology of antisense oligonucleotides -- Pharmacokinetics and pharmacodynamics of antisense oligonucleotides -- Tissue distribution, metabolism and clearance -- Hybridization-independent effects : principles and specific considerations for oligonucleotide drugs -- Hybridization-dependent effects : the prediction, evaluation and consequences of unintended target hybridization -- Class-related proinflammatory effects -- Exaggerated pharmacology -- Genotoxicity tests for novel oligonucleotide-based therapeutics -- Reproductive and developmental toxicity testing strategies for oligonucleotide-based therapeutics -- Specific considerations for preclinical development of inhaled oligonucleotides -- Lessons learned in oncology programs -- Inhaled antisense for treatment of respiratory disease -- Antisense oligonucleotides for treatment of neurology diseases -- Nucleic acids as adjuvants -- Splice-switching oligonucleotides -- CMC aspects for the clinical development of spiegelmers. 606 $aOligonucleotides$xTherapeutic use 606 $aAntisense nucleic acids$xTherapeutic use 615 0$aOligonucleotides$xTherapeutic use. 615 0$aAntisense nucleic acids$xTherapeutic use. 676 $a572.8/5 702 $aFerrari$b Nicolay$f1969- 702 $aSeguin$b Rosanne 906 $aBOOK 912 $a9910555194803321 996 $aOligonucleotide-Based Drugs and Therapeutics$92815752 997 $aUNINA LEADER 01020nam a22002531i 4500 001 991001197499707536 005 20031021161535.0 008 040407s1966 it |||||||||||||||||ita 035 $ab12733696-39ule_inst 035 $aARCHE-071333$9ExL 040 $aDip.to Scienze Storiche$bita$cA.t.i. Arché s.c.r.l. Pandora Sicilia s.r.l. 082 04$a398.9 100 1 $aParlangèli, Oronzo$0192713 245 10$aBibliografia dialettale italiana (1962- 1966) /$cOronzo Parlangeli 260 $aTaranto :$bJonica editrice,$c1966 300 $aP. 93-216 ;$c24 cm 500 $aEstr. da: Bollettino della carta dei dialetti italiani, 1(1966) 650 4$aDialetti italiani$xBibliografia 907 $a.b12733696$b02-04-14$c16-04-04 912 $a991001197499707536 945 $aLE009 STOR.10.5-20$g1$iLE009A-131 MSM$lle009$o-$pE0.00$q-$rn$so $t0$u0$v0$w0$x0$y.i13268314$z16-04-04 996 $aBibliografia dialettale italiana (1962- 1966$9268497 997 $aUNISALENTO 998 $ale009$b16-04-04$cm$da $e-$fita$git $h0$i1